Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

Major Program

Phase 0 I II Cancer Prevention Clinical Trials Program

Research Group

Gastrointestinal and Other Cancers

Status

Active, not recruiting

NCT ID

NCT02772003

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA) vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or progresses over a long period of time. Vaccines made from DNA may help the body build an effective immune response to kill cancer cells that express HCV infection.

Intervention

Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Rocakinogene Sifuplasmid

Condition

Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma

Investigators

Jeffrey M Jacobson

See list of participating sites